{"protocolSection":{"identificationModule":{"nctId":"NCT01104467","orgStudyIdInfo":{"id":"11764A"},"organization":{"fullName":"Lundbeck Japan K. K.","class":"INDUSTRY"},"briefTitle":"Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke","officialTitle":"Randomised, Double-blind, Placebo-controlled, Dose-escalation Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke","acronym":"DIAS-J"},"statusModule":{"statusVerifiedDate":"2021-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-08"},"primaryCompletionDateStruct":{"date":"2013-08","type":"ACTUAL"},"completionDateStruct":{"date":"2013-08","type":"ACTUAL"},"studyFirstSubmitDate":"2010-04-08","studyFirstSubmitQcDate":"2010-04-13","studyFirstPostDateStruct":{"date":"2010-04-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-08-30","lastUpdatePostDateStruct":{"date":"2021-08-31","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Lundbeck Japan K. K.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of the study is to evaluate whether desmoteplase is safe and tolerated when given to Japanese patients with acute ischemic stroke","detailedDescription":"The study is a safety and tolerability study of desmoteplase in Japanese patients with acute ischemic stroke. The study will test two doses"},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["Acute Ischemic Stroke","Desmoteplase","Japan","Safety","Stroke","Tolerability"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":48,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Desmoteplase 70 µg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Desmoteplase"]},{"label":"Desmoteplase 90 µg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Desmoteplase"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"Desmoteplase","description":"1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)","armGroupLabels":["Desmoteplase 70 µg/kg"]},{"type":"DRUG","name":"Desmoteplase","description":"1 bolus injection of desmoteplase 90 µg/kg (IV)","armGroupLabels":["Desmoteplase 90 µg/kg"]},{"type":"OTHER","name":"Placebo","description":"1 bolus injection of placebo IV","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"To evaluate the safety and tolerability of desmoteplase doses of 70 µg/kg and 90 µg/kg in Japanese patients with acute ischemic stroke as measured by the presence of symptomatic intracranial haemorrhage (sICH) within 72 hours after IMP","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"To evaluate the clinical improvement at Day 90 after administration of Investigational Medicinal Product (IMP) as measured by modified Rankin Scale (mRS)","timeFrame":"90 days"},{"measure":"To evaluate the clinical improvement at Day 7 and 30 after administration of IMP as measured by modified Rankin Scale (mRS)","timeFrame":"Day 7 and Day 30"},{"measure":"To evaluate recanalisation at 18±6 hr after administration of IMP","timeFrame":"18±6 hr after administration of IMP"},{"measure":"To evaluate change in infarct size at 18±6 hr relative to pre-treatment infarct size","timeFrame":"18±6 hr after administration"},{"measure":"To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of desmoteplase","timeFrame":"0.5 - 9 hr"},{"measure":"To evaluate the immunogenicity of desmoteplase","timeFrame":"Day 7, Day 30, Day 90"},{"measure":"To explore the predictive value of different volumes of absolute mismatch for the clinical response and other objectives","timeFrame":"Day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of acute ischemic stroke\n* Provided Informed Consent\n* Male or female\n* Aged between 20 and 85 years inclusive\n* Treatment within 3-9 hr after onset of stroke symptoms.\n* NIHSS score of 4-24 inclusive with clinical signs of hemispheric infarction\n* Must receive IMP within 60 minutes after brain imaging\n* Cerebral artery occlusion or high-grade stenosis in MCA\n\nExclusion Criteria:\n\n* Pre-stroke mRS score of \\>1\n* Previously exposed to desmoteplase\n* Scores \\>2 on NIHSS question 1a indicating coma\n* History or clinical presentation of ICH, subarachnoid haemorrhage (SAH), arterio-venous malformation (AVM), moyamoya disease, cerebral neoplasm or aneurysm\n* Current use of oral anticoagulants and a prolonged prothrombin time (INR \\>1.6)\n* Treated with heparin in the previous 48 hours and has a prolonged partial thromboplastin time\n* Baseline platelet count \\<100,000/mm3\n* Baseline haematocrit of \\<0.25\n* Baseline blood glucose \\<50 mg/dl or \\>200 mg/dl\n* Uncontrolled hypertension defined by a blood pressure, systolic \\>185 mmHg or diastolic \\>110 mmHg on at least 2 separate occasions at least 10 minutes apart\n* Patient has hereditary or acquired hemorrhagic diathesis\n* Gastrointestinal or urinary bleeding within the past 21 days\n* Arterial puncture in a non-compressible site within the previous 7 days\n* Another stroke or a serious head injury in the past 6 weeks\n* Major surgery or serious injury, including other sites than the head, within the preceding 14 days\n* Seizure at the onset of stroke\n* Acute myocardial infarction (AMI) within the previous 3 weeks\n* Thrombolytic within the previous 72 hr\n* Pregnant\n\nOther inclusion and exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Email contact via H. Lundbeck A/S","affiliation":"LundbeckClinicalTrials@lundbeck.com","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"JP006","city":"Akita","zip":"010-0874","country":"Japan","geoPoint":{"lat":39.71667,"lon":140.10826}},{"facility":"JP021","city":"Fukuoka","zip":"810-8563","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"JP018","city":"Hiroshima","zip":"734-8551","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"JP007","city":"Isesaki","zip":"374-0006","country":"Japan","geoPoint":{"lat":36.31667,"lon":139.2}},{"facility":"JP024","city":"Kagoshima","zip":"892-0853","country":"Japan","geoPoint":{"lat":31.56667,"lon":130.55}},{"facility":"JP011","city":"Kawasaki","zip":"216-8511","country":"Japan","geoPoint":{"lat":35.52056,"lon":139.71722}},{"facility":"JP015","city":"Kobe","zip":"650-0046","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"JP022","city":"Kumamoto","zip":"861-4193","country":"Japan","geoPoint":{"lat":32.80589,"lon":130.69182}},{"facility":"JP012","city":"Nagoya","zip":"466-8650","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"JP026","city":"Nishinomiya","zip":"662-0934","country":"Japan","geoPoint":{"lat":34.71562,"lon":135.33199}},{"facility":"JPO17","city":"Okayama","zip":"701-0192","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"JP002","city":"Sapporo,Hokkaido","zip":"006-8555","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"JP001","city":"Sapporo","zip":"060-8570","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"JP004","city":"Sendai","zip":"982-0012","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"JP005","city":"Shibata","zip":"989-1253","country":"Japan","geoPoint":{"lat":37.95,"lon":139.33333}},{"facility":"JP014","city":"Suita","zip":"565-8565","country":"Japan","geoPoint":{"lat":34.76143,"lon":135.51567}},{"facility":"JP020","city":"Tokushima","zip":"770-8503","country":"Japan","geoPoint":{"lat":34.06667,"lon":134.56667}},{"facility":"JP009","city":"Tokyo","zip":"145-0065","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"JP013","city":"Toyota","zip":"471-8513","country":"Japan","geoPoint":{"lat":35.08333,"lon":137.15}}]},"referencesModule":{"references":[{"pmid":"26251244","type":"DERIVED","citation":"Mori E, Minematsu K, Nakagawara J, Hasegawa Y, Nagahiro S, Okada Y, Truelsen T, Lindsten A, Ogawa A, Yamaguchi T; DIAS-J Investigators. Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke. Stroke. 2015 Sep;46(9):2549-54. doi: 10.1161/STROKEAHA.115.009917. Epub 2015 Aug 6."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000069588","term":"Salivary plasminogen activator alpha 1, Desmodus rotundus"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M144272","name":"Salivary plasminogen activator alpha 1, Desmodus rotundus","asFound":"Percutaneous Endoscopic Gastrostomy","relevance":"HIGH"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}